On the bioactive conformation of NAN-190 (1) and MP3022 (2), 5-HT1A receptor antagonists

被引:40
作者
Paluchowska, MH
Mokrosz, MJ
Bojarski, A
Wesolowska, A
Borycz, J
Charakchieva-Minol, S
Chojnacka-Wójcik, E
机构
[1] Polish Acad Sci, Inst Pharmacol, Dept Med Chem, PL-31343 Krakow, Poland
[2] Polish Acad Sci, Inst Pharmacol, Dept New Drug Res, PL-31343 Krakow, Poland
关键词
D O I
10.1021/jm991045h
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Structural modifications of 1, a postsynaptic 5-HT1A receptor antagonist, provided its flexible (8, 12) and rigid (7, 9, 11, 13) analogues; Compounds 7, 8, 9, and 11 showed high 5-HT1A receptor affinity (K-i = 4-72 nM). They acted as 6-HT1A postsynaptic receptor antagonists, since, like 1, they inhibited the behavioral syndrome, i.e., flat body posture (FBP) and forepaw treading (FT), in reserpine-pretreated rats as well as the lower lip retraction (LLR) in rats, both induced by 8-hydroxy-2-(di-n-propylamino)tetralin hydrobromide (8-OH-DPAT), a 5-HT1A receptor agonist. Compound 12, which demonstrated high 6-HT1A receptor affinity (K-i = 50 nM), revealed properties of a partial 5-HT1A receptor agonist: it induced LLR and, at the same time, inhibited FT in rats. Compound 13 (K-i = 1600 nM) was not tested in a behavioral study. Restriction of the conformational freedom in 2, a full 5-HT1A receptor antagonist, yielded compound 14 with high 5-HT1A receptor affinity (K-i = 47 nM) and partial agonist properties at postsynaptic 5-HT1A receptors in the above tests in vivo; i.e., it induced LLR and inhibited FBP and FT in rats. New constrained analogues of 1 and 2 (compounds 7 and 14, respectively) were also synthesized to recognize a bioactive conformation of those 5-HT1A receptor antagonists. On the basis of in vitro and in vivo investigations, binding and functional properties of compound 7 were found to reflect those of 1 at 5-HT1A receptors. On the other hand, compound 14, a rigid analogue of 2, showed a different activity in vivo in comparison with the parent compound. PM3 and MM calculations revealed the existence of three! low-energy conformers of 7 and six of 14, all of them belonging to the extended family of conformations. The optimized structures of both analogues had a different angle between aromatic planes of terminal fragments; moreover, the heteroaromatic system of those molecules occupied various space regions. Our present study provides support to the hypothesis that the bioactive conformation of 1, responsible for its postsynaptic 5-HT1A receptor antagonism, is an extended linear structure represented by 7.
引用
收藏
页码:4952 / 4960
页数:9
相关论文
共 30 条
[1]   3-DIMENSIONAL QUANTITATIVE STRUCTURE-ACTIVITY-RELATIONSHIPS OF 5-HT RECEPTOR-BINDING DATA FOR TETRAHYDROPYRIDINYLINDOLE DERIVATIVES - A COMPARISON OF THE HANSCH AND COMFA METHODS [J].
AGARWAL, A ;
PEARSON, PP ;
TAYLOR, EW ;
LI, HB ;
DAHLGREN, T ;
HERSLOF, M ;
YANG, YH ;
LAMBERT, G ;
NELSON, DL ;
REGAN, JW ;
MARTIN, AR .
JOURNAL OF MEDICINAL CHEMISTRY, 1993, 36 (25) :4006-4014
[2]   SELECTIVE ACTIVATION OF 5HT1A RECEPTORS INDUCES LOWER LIP RETRACTION IN THE RAT [J].
BERENDSEN, HHG ;
JENCK, F ;
BROEKKAMP, CLE .
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1989, 33 (04) :821-827
[3]  
BOJARSKI AJ, 1993, PHARMAZIE, V48, P289
[4]  
CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099
[5]   MODELS OF 5-HYDROXYTRYPTAMINE RECEPTORS - A REVIEW [J].
CHILMONCZYK, Z .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1995, 47 (10) :791-801
[6]   Conformational analysis and theoretical quantitative size and shape-affinity relationships of N-4-protonated N-1-arylpiperazine 5-HT1A serotoninergic ligands [J].
Cocchi, M ;
Fanelli, F ;
Menziani, MC ;
DeBenedetti, PG .
JOURNAL OF MOLECULAR STRUCTURE-THEOCHEM, 1997, 397 :129-145
[7]   Stereochemistry of serotonin receptor ligands from crystallographic data. Crystal structures of NAN-190.HBr, 1-phenylbiguanide, MDL 72222 and mianserin. HCl and selectivity criteria towards 5-HT1, 5-HT2 and 5-HT3 receptor subtypes [J].
Dalpiaz, A ;
Ferretti, V ;
Gilli, P ;
Bertolasi, V .
ACTA CRYSTALLOGRAPHICA SECTION B-STRUCTURAL SCIENCE, 1996, 52 :509-518
[8]  
DIJKSTRA GDH, 1993, RECL TRAV CHIM PAY B, V112, P151
[9]  
El-Bermawy M.A., 1992, MED CHEM RES, V2, P290
[10]  
Filip Malgorzata, 1996, Polish Journal of Pharmacology, V48, P397